Protection against Leishmania major challenge infection in mice vaccinated with live recombinant parasites expressing a cytotoxic gee

Journal of Infectious Diseases

Volumn 177, Issue 1, 1998, Pages 188-195

  Muyombwe, Anthony ^b   Olivier, Martin ^d   Harvie, Pierrot ^c   Bergeron, Michel G ^d   Ouellette, Marc ^d   Papadopoulou, Barbara ^a  

^a LAVAL UNIVERSITY   (Canada)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ANIMAL EXPERIMENT; ARTICLE; HOST PARASITE INTERACTION; IMMUNIZATION; INFECTION CONTROL; INFECTION SENSITIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031985934     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513821     Document Type: Article

References (15)

1. Ouellette M, Papadopoulou B. Mechanisms of drug resistance in Leishmania. Parasitol Today 1993;9:150-3.
2. Howard JG, Nicklin S, Hale C, Liew FY. Prophylactic immunization against experimental leishmaniasis. I. Protection in mice genetically vulnerable to fatal Leishmania tropica infection. J Immunol 1982;129:2206-12.
3. Handman E, Mitchell GF. Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis. Proc Natl Acad Sci USA 1985;82:5910-5.
4. Scott P, Pearce E, Notovitz P, Sher A. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. J Immunol 1987;139:221-7.
5. Gorczynski RM. Altered virulence and vaccination properties of Leishmania parasites grown in infected vaccinated mice. Infect Immun 1989;57:2430-3.
6. Yang DM, Fairweather N, Button L, McMaster WR, Kahl LP, Liew FY. Oral Salmonella typhimurium (AroA) vaccine expressing a major leishmanial surface protein (gp63) preferentially induced Th1 cells and protective immunity against leishmaniasis. J Immunol 1990;145:2281-7.
7. -). Immunology 1995;85:1-7.
8. Connell ND, Medina-Acosta E, McMaster RW, Bloom BR, Russell DG. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63. Proc Natl Acad Sci USA 1993;90:11473-7.
9. Mougneau E, Altare F, Wakil AE, et al. Expression cloning of a protective Leishmania antigen. Science 1995;268:563-6.
10. Titus RG, Gueiros-Filho FJ, de Freitas LAR, Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci USA 1995;92:10267-71.
11. Liew FY. Functional heterogeneity of CD4 T cells in leishmaniasis. Immunol Today 1989;10:40-5.
12. Locksley MR, Louis JA. Immunology of leishmaniasis. Cur Opin Immunol 1992;4:413-8.
13. Reed SO, Scott P. T cell and cytokine responses in leishmaniasis. Cur Opin Immunol 1993;5:524-31.
14. LeBowitz JH, Cruz A, Beverley SM. Thymidine kinase as a negative selectable marker in Leishmania major. Mol Biochem Parasitol 1992;51:321-6.
15. Muyombwe A, Olivier M, Ouellette M, Papadopoulou B. Selective killing of Leishmania amastigotes expressing a thymidine kinase suicide gene. Exp Parasitol 1997;85:35-42.